Asensus Surgical, Inc. (ASXC) recently announced that the Loginov Moscow Clinical Scientific Center has purchased its Senhance Surgical System. ASXC is a medical device company, which is focused on digitizing the interface between the surgeon and patient.
Following the news, shares of the company gained 1.6% on Monday. The stock, however, pared its gains by 1.1% to close at $1.89 in extended trade.
Senhance Surgical System is a digital laparoscopic platform that harnesses the power of machine learning to cure its patients by providing surgical assurance through haptic feedback, eye-tracking camera control and 3D visualization. It is also the first platform to offer 3 mm instruments.
The CEO of Asensus Surgical, Anthony Fernando, said, “We are thrilled to be partnering with such an innovative, forward-thinking institution for our first Senhance program within Russia. We share a commitment to advancing patient outcomes through the use of new minimally invasive technologies and look forward to helping Loginov expand their offerings to patients.’’ (See Asensus Surgical stock chart on TipRanks)
The stock has a Moderate Buy consensus rating based on 1 Buy. Two months ago, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy on the stock with a price target of $4 (109.4% upside potential). Shares of the company have gained 445.7% over the past year.
Related News:
Ford Recalls Nearly 39,000 Mustang Mach-E SUVs — Report
IBM Wins Wheat Silos Automation Project in Egypt
Uber Deepens Partnership with Rite Aid; Street Says Buy
